FY 2025 (No.418-)
| Issue |
No. |
Table of contents |
| August 2025 |
422 |
Full text [443 KB]
- Article 3. Revisions of PRECAUTIONS (No.362)
Article 3.-1 [1] Semaglutide (genetical recombination),[2] Tirzepatide,[3] Insulin glargine (genetical recombination)/lixisenatide (and 4 others)
- Article 4. List of Products Subject to Early Post-marketing Phase Vigilance
|
| July 2025 |
421 |
Full text [676 KB]
- Article 1. Mandatory Registration of Pharmaceuticals, Medical Devices, etc. in a Product Database, and Utilization of Barcodes .
- Article 2. Important Safety Information
Article 2.-1 Thiamazole
- Article 3. Revisions of PRECAUTIONS (No.361)
Article 3.-1 Desmopressin acetate hydrate (oral dosage form) (and 2 others)
- Article 4. List of Products Subject to Early Post-marketing Phase Vigilance
|
| June 2025 |
420 |
Full text [667 KB]
|
| May 2025 |
419 |
Full text [507 KB]
- Article 1. The Manuals for Management of Individual Serious Adverse Drug Reactions
- Article 2. Revisions of PRECAUTIONS (No.359)
Article 2.-1 Desmopressin acetate hydrate (and 3 others)
- Article 3. List of Products Subject to Early Post-marketing Phase Vigilance
|
| April 2025 |
418 |
Full text [684 KB]
- Article 1. Efforts Against Abuse of Over-the-Counter Drugs
- Article 2. Important Safety Information
Article 2.-1 Dulaglutide (genetical recombination)
- Article 3. Revisions of PRECAUTIONS (No.358)
Article 3.-1 Dulaglutide (genetical recombination) (and 4 others)
- Article 4. List of Products Subject to Early Post-marketing Phase Vigilance
|
